Upcoming Earnings Overview for GoodRx Holdings in Q2 2025
GoodRx Holdings, Inc. (GDRX) has announced its Q2 2025 financial results, revealing a pattern of slow growth and modest earnings. The company's revenue slightly missed estimates, while adjusted EPS was down 10% compared to analyst expectations.
In Q2 2025, GoodRx reported an adjusted EPS of $0.09 per share, which missed the analyst estimate of $0.10 per share by 10%. Revenue for the quarter was $203.1 million, a 1.2% year-over-year growth but a 1% miss relative to expectations.
Key performance highlights from Q2 2025 include:
- EPS: $0.09 vs. estimate $0.10 (miss)
- Revenue: $203.1 million vs. estimate $205.7 million (miss)
- Adjusted EBITDA and operating margin improved somewhat but still fell slightly short of analyst expectations
Historically, GoodRx has underperformed both EPS and revenue estimates over the past four quarters, indicating a pattern of modest underperformance.
Looking ahead, GoodRx has provided revenue guidance for 2025, with an expected range of $810M-$840M. The company did not provide specific EPS expectations for Q1 2025 or Q2 2025 in this announcement.
GoodRx's Q2 2025 actuals mostly aligned or slightly missed the latest available estimates just before reporting, which were about:
- EPS: Around $0.10 per share
- Revenue: Around $205.7 million
GoodRx will announce its Q2 earnings results on Wednesday, August 6th, after market close. The company's Q1 2025 Earnings Call Transcript was recently released.
In other news, GoodRx announced a new subscription service focused on erectile dysfunction treatments. Over the last 3 months, EPS estimates for GoodRx have seen 2 upward revisions and 3 downward revisions, while revenue estimates have seen 5 upward revisions and 8 downward revisions.
| Metric | Q2 2025 Actual | Estimate | Surprise | |-------------------|----------------|------------------|-------------------| | EPS (Adjusted) | $0.09 | $0.10 | -10% | | Revenue | $203.1M | $205.7M | -1% |
The company did not mention any specific health care legislation or policy that they are a beneficiary of in this announcement. GoodRx's stock price has declined since early 2025 despite a Buy analyst consensus and price target optimism.
Despite the slow growth and modest earnings in Q2 2025, GoodRx is planning to invest in a new subscription service for erectile dysfunction treatments. The company's stock price, however, has seen a decline since early 2025, indicating a potential concern in the finance sector for investors.
